Ferdinand Belga

Ferdinand Belga Email and Phone Number

Founder and CEO @ Ascertain Biotech, Inc
Chicago, IL, US
Ferdinand Belga's Location
Greater Chicago Area, United States, United States
Ferdinand Belga's Contact Details

Ferdinand Belga personal email

About Ferdinand Belga

*Founder & CEO of the leader in AI Guided Patient Management (3 Divisions: AI Plastic Surgery, AI Spine/Pain and AI Depression Management) to solve problems of poor patient outcomes (e.g. misdiagnosis and poor treatment strategies). First to launch the objective, quantitative blood test/biomarker to diagnose and manage depression. AI minimizes bias in patient care and provides better patient outcomes, including personalized medicine for antidepressants to an individual patient.*C-level executive serving to provide potential treatments in underserved, high unmet need diseases such as opioid addiction, rare diseases, medical devices, etc. Maximize successful capital raise to further clinical development and potential NDA submission. Company Lead for successful fund-raising through value maximization.*Strategic Cross-Functional and Cross-Divisional Experience at Several Leadership Roles at Abbott Laboratories and a Private Equity Funded Pharma Start-Up Company. Complimented by Biotechnology and Rare Diseases Executive experience, this positions leadership and support to several aspects of the industry from start-up through scalability. *Track Record of Leading High Performing Teams that exceeds commitments. *Turned around teams and businesses to leadership positions. Global experience across Developed and Emerging Markets. *Recognized Launch Expertise across various markets. Award-winning performance across various Divisions and Functions.Pharmaceuticals and Biotechnology Functional Experience includes:• Start-Up: from Capital Raise through Launch/Exit experience.• Corporate Office: Business Development/Acquisitions/Licensing. Key Strategic Initiatives for Corporate Growth and strengthen Key Therapeutic Areas.• Full P&L Responsibilities for ~$110 Million Franchise in the Russian Emerging Market (with 2 Market Leading Products in 2 Therapeutic Areas). Per IMS 2012, achieved Fastest Growing Women's Health Business in Russia. • International Marketing, Sales, Sales Force Effectiveness for Emerging Markets (Russia, India, China, CIS)• International Marketing/ Business Development/Acquisitions/Licensing• US Sales/Sales Management Biotechnology and Pharmaceuticals• International Marketing Hospital Products Specialty Generics• Engineering• QA• Operations• Manufacturing and Operations• Univ Research• Speaker and Moderator at International Conferences

Ferdinand Belga's Current Company Details
Ascertain Biotech, Inc

Ascertain Biotech, Inc

View
Founder and CEO
Chicago, IL, US
Ferdinand Belga Work Experience Details
  • Ascertain Biotech, Inc
    Founder And Ceo
    Ascertain Biotech, Inc
    Chicago, Il, Us
    View
  • Ascertain Biotech, Inc
    Founder & Ceo
    Ascertain Biotech, Inc 2023 - Present
    Humbled to serve many patients with AI biotechnology with the goal of better patient outcomes and reducing healthcare costs.Ascertain Biotech's AI minimizes the enemy of good patient outcomes- BIAS. Ascertain's AI analyzes various patient, manufacturer and pharmaceuticals to provide patients/surgeons a strategic predictive outcomes blueprint that maximizes clinical success.Ascertain Biotech is comprised of 3 Divisions: AI Spine Surgery, AI Plastic Surgery and AI Depression Management.Additionally, Ascertain will have the first quantitative and objective measure for depression diagnosis via a biomarker, if approved. The AI may also provide a personalized medicine approach on which available anti-depressant may have the best outcome for each individual patient.The AI Surgical Blueprints are the key for surgeons to maximize patient outcomes in spine and plastic surgery (including facial recognition to be applied to children's cleft palates and facial plastic surgery).
    View
  • University Of Illinois Urbana-Champaign
    Adjunct Faculty
    University Of Illinois Urbana-Champaign 2023 - Present
    Champaign, Il, Us
    Adjunct Faculty at the iSchool (School of Information Sciences)- US News & Report Rank #1. Developing our UIUC iSchool students in preparation for careers in data sciences, consulting with the BIG (Business Intelligence Group), practicum, etc"U.S. News & World Report has once again named the iSchool at Illinois the top graduate school for library and information studies, based on national rankings of accredited master's degree programs. The iSchool has held the top spot since 1996.""This recognition confirms our School's preeminence in teaching, research, and engagement," said Dean Eunice E. Santos. "Our School prepares students to succeed in a competitive job market and advances research that addresses contemporary challenges in society. Our strength lies in our multifaceted approach, which pushes the boundaries of creativity and embraces diversity and inclusion."https://www.usnews.com/best-graduate-schools/top-library-information-science-programs/university-of-illinois-at-urbana-champaign-145637https://ischool.illinois.edu/news-events/news/2021/03/ischool-illinois-ranked-number-one#:~:text=U.S.%20News%20%26%20World%20Report%20has,the%20top%20spot%20since%201996https://ischool.illinois.edu/engage/BIG***Bill Gates quotes that Microsoft hires CS graduates from U of I more than any other university in the world.***https://mediaspace.illinois.edu/media/Bill+Gates+on+Computer+Science+and+Innovation/1_ck3nl1s9/9983471
    View
  • National Science Foundation (Nsf)
    Entrepreneur Mentor
    National Science Foundation (Nsf) Jan 2023 - Present
    Alexandria, Va, Us
    Mentor to the U.S. National Science Foundation’s Innovation Corps (I-Corps™) program --> an immersive, entrepreneurial training program that facilitates the transformation of invention to impact. 2023 includes SmarTreatMate. https://smartreatmate.com/https://new.nsf.gov/funding/initiatives/i-corps/about-i-corpsWidely recognized as an effective training program in the U.S. and internationally, I-Corps addresses three urgent national needs:1) Training an entrepreneurial workforce2) Bringing cutting-edge technologies to market and enabling positive economic impact3) Nurturing an innovation ecosystem
    View
  • Matter
    Entrepreneur In Residence|Mentor
    Matter Mar 2019 - Present
    Chicago, Illinois, Us
    Mentor at Startup Incubator on Entrepreneurship, Pharmaceutical, Medical Device, Financing.In 2022 and 2023, MATTER has partnered with the Korea Small-Medium Enterprises (SMEs) and Startups Agency (KOSME) to launch the U.S. Market Adoption Program aimed at preparing a cohort of Korean companies for U.S. market success and I have the privilege to mentor these Korean SME start ups.
    View
  • Northwestern University - Kellogg School Of Management
    Guest Lecturer
    Northwestern University - Kellogg School Of Management Jan 2016 - Present
    Evanston, Illinois, Us
    Lectured to EMBA, Full Time and Part Time Kellogg students on entrepreneurship, strategy, life cycle management/product innovation, healthcare, global licensing/acquisitions (BD), global marketing. Served on several panels and lectured across different Kellogg campuses.
    View
  • Elandas
    Member Of The Board Of Directors
    Elandas Nov 2014 - Present
    Saint John, New Brunswick, Ca
    Responsibilities: Advisory and Strategic Consulting. Advising on formation of business structures to maximize launches, profitability, cash flows, financial leverage, marketing and sales strategies.
    View
  • Spinal Resources, Inc.
    Chief Operating Officer
    Spinal Resources, Inc. 2020 - 2021
    Company lead for operations and investor relations. Recent clearance of the Swedge™ Stabilization System marks the transition of Spinal Resources, Inc. from design and distribution experts into full manufacturers of unique surgical enhancements. Revenue continues to grow since launch July 2019.The Swedge™ System, the most advantageous project in the company’s pipeline, was designed with a comprehensive development plan exclusively with private funding, to assure full responsibility for its advancement and success.
  • Mindmed
    Pre-Commercialization
    Mindmed 2019 - 2020
    New York, Ny, Us
    Mindmed discovers, develops, and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.
    View
  • Mindmed
    Chief Business Officer
    Mindmed 2018 - 2019
    New York, Ny, Us
    Successfully raised capital for lead asset that will potentially benefit those affected by the opioid crisis with a first-in-class treatment that targets the rewards center of the brain (key differentiation is our approach to treat this as a disease). MindMed, Inc absorbed SavantHWP via an RTO. Savant HWP was founded in 2009 to develop disease modifiers/pharmaceutical products that improve health, maintain wellness and prevent disease with the greatest impact.Savant’s novel approach targets the dopamine “reward” pathway in the brain that drives pleasure-seeking behaviors associated with addiction and obesity. Targeting the brain’s central reward pathway enables Savant to develop drug candidates potentially effective against all forms of pleasure seeking behavior. Data from animal models demonstrate the efficacy of Savant’s approach in a broad array of substance addictions, including cocaine, opiate, methamphetamine, nicotine and alcohol and in obesity. Savant’s lead compound, 18-MC, is an orally active, α3β4 nicotinic receptor antagonist that modulates dopamine fluctuations in the mesolimbic system of the brain and prevents drug abuse in animal addiction models. The α3β4 nicotinic receptor has recently been validated as an anti-addiction drug target with independent confirmation that polymorphisms in the α5α3β4 gene cluster on chromosome 15 are predictive of heavy smoking and severe nicotine dependence. 18-MC completed Phase I human clinical trials. Savant’s approach is unique in addiction medicine. Current medications are either agonists or antagonist for the addictive substance’s primary receptor site of action and are themselves often dangerous and addictive. These types of receptor strategies do not directly target the underlying addictive mechanism in the brain - fluctuations of dopamine in the mesolimbic system leading to drug craving - which are targeted by Savant’s approach.
    View
  • Bellesoma
    Chief Operating Officer
    Bellesoma 2019 - 2020
    Chicago, Il, Us
    Developing state of the art AI surgical systems to support women's wellbeing and aging. The System has AI topography scans and a novel, innovative surgical technique using the woman's own tissue.
    View
  • Point Of Care Network
    Senior Vice President, Client Services
    Point Of Care Network 2017 - 2018
    Boonton, New Jersey, Us
    Strategic and Tactical Executive for the pharmaceutical and medical device industry to maximize leadership positions (company and products). Global role for US and EU presence for 2017. The next 5 years will expand towards Global Reach in Latin America and Asia. Rare disease and Biologics focus. Encompasses Commercial, Medical, and Business Development.
    View
  • The Northbrook Symphony Orchestra, Inc.
    Member Board Of Directors
    The Northbrook Symphony Orchestra, Inc. Jun 2016 - Oct 2017
    Northbrook, Il, Us
    http://www.northbrooksymphony.org/
    View
  • Marathon Pharmaceuticals, Llc
    Senior Director Of Marketing And Patient Advocacy
    Marathon Pharmaceuticals, Llc 2014 - 2017
    Strategic and Tactical Director leading 2 key Growth Drivers at a Private Equity Funded Company, Marathon Pharmaceuticals, LLC (a leader in the development, manufacturing and commercialization of specialty pharmaceuticals to treat rare diseases for high need populations). Strategic Lead, reporting to the CCO, on a developmental product to treat Duchenne Muscular Dystrophy through commercialization. Product Launched in Feb 9, 2017. Product sold via M&A Q2 2017 to PTC Therapeutics. Strategic and Commercial Lead on a 2014 Product Launch to address unmet hospital needs for pediatric and adult pain management market. Understanding of the pharmaceutical commercialization process: from financing, development, clinical, regulatory through commercial launch of products to treat rare diseases. Lead a Development Team (Clinical, Market Research, Business Development) and lead a Commercial Team (Marketing; Sales indirectly).
  • Abbott
    Director- Corporate Acquisitions/Licensing/Business Development
    Abbott 2013 - 2014
    Abbott Park, Illinois, Us
    Strategic Global Initiatives for Corporate Growth across Abbott Divisions for Immediate and Long Term Growth across Key Therapeutic Areas. Contribute to Abbott's external pipeline with partnerships, licensing, acquisitions and development. Negotiate across internal and external partnerships to achieve maximal return and profitability.
    View
  • Abbott
    Business Unit Director- Women'S And Men'S Health & Business Development In Russia (Emerging Market)
    Abbott 2011 - 2013
    Abbott Park, Illinois, Us
    Achieved New Record of Sales and Growth & Achieved the Fastest Growing Women's Health Business in Russia, Per IMS 2012. Strategic and Tactical Director for ~$110 Million Dollar Franchise in Russia which includes Duphaston and Femoston (Market Leading Products in the Russian Market for each Therapeutic Area). Expanding Growth Opportunities to impact current sales and build for future expansion in this Emerging Market. -Led this Turn-Around from 18 months of flat sales prior to joining the BU to Record Growth and Record Sales. Responsible for complete P&L for the Women and Men's Health Franchise (Marketing & Sales). Also was responsible for the Business Development/Acquisitions/New Product Initiatives for the entire Russia Established Products Division (which is the largest affiliate globally for the Emerging/Established Products Division).
    View
  • Abbott Laboratories
    Commercial Director Emerging Markets
    Abbott Laboratories 2008 - 2010
    Abbott Park, Illinois, Us
    Award winning Emerging Markets- Russia, India and China (Fastest Growth). Develop and Maximize Sales, Sales Force Effectiveness and HUMIRA Marketing. Elevate to Global Excellence the Business Strategies and Sales Forces in these Emerging Markets. Effectively lead the Sales Force Integration of Solvay and Abbott across Russia, India and China. Lead the Acceleration of Sales Force Hiring, Training, Effectiveness for India and China (doubled the sales force from ~2,000 to ~4,000 in one year). Partnered with McKinsey and IMS for the Growth and Development of the Emerging Market Business Structures for Russia, India and China.
    View
  • Abbvie
    Sales Manager-Immunology
    Abbvie 2005 - 2008
    North Chicago, Illinois, Us
    Award Winning Performance demonstrating Leadership in the Launch of HUMIRA and Biologics Market for Rheumatology, Dermatology and Gastroenterology Specialties- covering 5 Midwest States- Illinois, Indiana, Michigan, Ohio and Kentucky. Multiple Award Winner including Fastest Growth for a Team in Launch Year. Team Members were Multiple Award Winners. Turned around a team from worst to first. Led other teams to lead positions.
    View
  • Abbvie
    Immunology Sales Training Program Manager
    Abbvie Dec 2004 - Dec 2006
    North Chicago, Illinois, Us
    Honored with Abbott PACE Award for Pioneering and Elevating the Training and Sales Force Standards in the Expansion of the HUMIRA (Biotechnology) Sales Force. Trained National Sales Force for the Immunology, Dermatology and Gastroenterology Launches
    View
  • Abbvie
    Territory Manager
    Abbvie 2000 - 2004
    North Chicago, Illinois, Us
    Multiple Award Winner for successful launches in HUMIRA and Anti-Infective Sales including: Best Launch Award for HUMIRA (flagship product for Abbott), Best Rep Awards for various sales forces, Ranked Top 10% of salesforce for ALL years for both Anti-Infective and HUMIRA Sales Forces.
    View
  • Abbott Laboratories
    Global Marketing And Business Development
    Abbott Laboratories Dec 1999 - Dec 2000
    Abbott Park, Illinois, Us
    Successful Launch and Development of the Specialty Generics Business for Abbott Laboratories. The Specialty Generics Business Unit was the harbinger of the Mature Business Operations (MBO) and Emerging Products Division (EPD) of Abbott Laboratories. Key Marketing, License and Acquisition, and Business Development across the Global Affiliates developed these Mature Products as successful adjunct business strategies.
    View
  • Abbott
    Various Cross-Functional/Cross-Divisional Roles (Professional Development Program)
    Abbott 1994 - 1999
    Abbott Park, Illinois, Us
    Various awards and recognition. Exceeded Expectations. QA Chemist, QA Stability, Raw Materials QA, Environmental Engineer, Inventory Control/Materials Management, Manufacturing Supervisor
    View

Ferdinand Belga Skills

Pharmaceutical Industry Product Launch Cross Functional Team Leadership Strategy Business Strategy Management Sales Effectiveness Marketing Strategy Pharmaceutical Sales Business Development Sales Operations Biotechnology New Business Development Sales Strategic Planning Sales Management Global Marketing Rheumatology Medical Devices Dermatology Cardiology Hospital Sales Business Planning P&l Management Selling Healthcare Immunology Negotiation Hospitals Product Development International Sales Product Marketing Change Management Clinical Research Global Business Development Coaching Competitive Intelligence Orphan Drugs Biopharmaceuticals Emerging Markets Pharmaceuticals Product Launches Strategy Development Licensing Team Building Consultative Selling Sales Force Effectiveness Generic Drugs Rare Diseases Launch Experience

Ferdinand Belga Education Details

  • Northwestern University - Kellogg School Of Management
    Northwestern University - Kellogg School Of Management
    Entrepreneurship]
  • Kellogg-Recanati Executive Mba Program At The Coller School Of Management
    Kellogg-Recanati Executive Mba Program At The Coller School Of Management
    Entrepreneurship/Entrepreneurial Studies
  • Harvard University
    Harvard University
    Chemistry
  • Insead
    Insead
    Executive Development-Blue Ocean Strategy/ Marketing
  • University Of Illinois Urbana-Champaign
    University Of Illinois Urbana-Champaign
    Biology-Pre Med
  • Stephen Tyng Mather High School
    Stephen Tyng Mather High School
  • Jamieson Elementary School
    Jamieson Elementary School

Frequently Asked Questions about Ferdinand Belga

What company does Ferdinand Belga work for?

Ferdinand Belga works for Ascertain Biotech, Inc

What is Ferdinand Belga's role at the current company?

Ferdinand Belga's current role is Founder and CEO.

What is Ferdinand Belga's email address?

Ferdinand Belga's email address is fe****@****ott.com

What schools did Ferdinand Belga attend?

Ferdinand Belga attended Northwestern University - Kellogg School Of Management, Kellogg-Recanati Executive Mba Program At The Coller School Of Management, Harvard University, Insead, University Of Illinois Urbana-Champaign, Stephen Tyng Mather High School, Jamieson Elementary School.

What skills is Ferdinand Belga known for?

Ferdinand Belga has skills like Pharmaceutical Industry, Product Launch, Cross Functional Team Leadership, Strategy, Business Strategy, Management, Sales Effectiveness, Marketing Strategy, Pharmaceutical Sales, Business Development, Sales Operations, Biotechnology.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.